About Marc

Marc is co-chair of Cooley’s global life sciences industry practice. For over 20 years, he has represented life sciences and other healthcare companies and investors in public and private transactions, including securities offerings, joint ventures and M&A matters. He also has extensive experience advising public companies boards of directors and management teams regarding Securities and Exchange Commission periodic disclosure, Sarbanes-Oxley compliance, corporate governance and Nasdaq and New York Stock Exchange rules.

View full bio

Passions

Road cycling

Skiing

Experience

Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma

Cooley Advises Special Committee of Checkpoint on Acquisition by Sun Pharma

March 9, 2025

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Read more

Related contacts

Bill Roegge
Partner, New York
Kevin Cooper
Partner, New York
Marc Recht
Partner, Boston
Wesley Dietrich
Associate, Washington, DC
Katie Benvenuti
Associate, New York
Michael Bergmann
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Alan W. Tamarelli
Partner, New York
Julia R. Brinton
Special Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Stella Sarma
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Karun Ahuja
Special Counsel, Chicago
Matthew Choy
Associate, New York
Jameson Davis
Associate, Boston
Kyle Hess
Associate, New York
Allison Kutner
Associate, New York
Breanna Qin
Associate, Palo Alto
Arda Can Tekin
Associate, New York
Ryan Vann
Partner, Chicago

Related Practices & Industries

Mergers and Acquisitions
Life Sciences
Healthcare
Capital Markets
Cyber/Data/Privacy
Antitrust and Competition
Compensation and Benefits
Life Sciences Corporate Partnering and Licensing
Tax
Labor and Employment
Life Sciences and Healthcare Regulatory
CFIUS

Enavate Sciences Co-Leads Normunity’s $75 Million Series B

Enavate Sciences Co-Leads Normunity’s $75 Million Series B

January 13, 2025

Cooley advised Enavate Sciences, a top investment firm, as the co-lead investor in the $75 million Series B financing round of Normunity, a biotechnology company creating novel anticancer therapies. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston
Liz Gold
Associate, New York
Stephanie Gentile
Partner, New York

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences
Tax

Enavate Sciences Invests in Aviceda Therapeutics $207.5 Million Series C

Enavate Sciences Invests in Aviceda Therapeutics $207.5 Million Series C

January 7, 2025

Cooley advised Enavate Sciences, a top investment firm, on its participation in the $207.5 million Series C financing round of Aviceda Therapeutics, a clinical-stage biotech company focused on developing next-generation immunomodulators. Lawyers Marc Recht, Brandon Fenn and Barry Kuang led the Cooley team advising Enavate Sciences.

Related contacts

Marc Recht
Partner, Boston
Brandon W. Fenn
Partner, New York
Barry Kuang
Associate, Boston

Related Practices & Industries

Life Sciences
Venture Capital
Emerging Companies

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

December 3, 2024

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
David Burns
Special Counsel, Washington, DC
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Partner, Brussels

Related Practices & Industries

Life Sciences Corporate Partnering and Licensing
Life Sciences
Antitrust and Competition
Mergers and Acquisitions
Tax
Cyber/Data/Privacy

Enavate Sciences Leads Sionna Therapeutics’ $182 Million Series C

Enavate Sciences Leads Sionna Therapeutics’ $182 Million Series C

March 6, 2024

Cooley advised Enavate Sciences, a top investment firm, as the lead investor in the $182 million Series C financing round of Sionna Therapeutics, a clinical-stage life sciences company dedicated to developing highly effective, differentiated treatments for cystic fibrosis. Partner Brandon Fenn led the Cooley team advising Enavate Sciences.

Related contacts

Brandon W. Fenn
Partner, New York
Alex Abelson
Associate, New York
Kirsten Roggeveen
Associate, New York
Steve Andersen
Associate, New York
Alan W. Tamarelli
Partner, New York
Michael Bruno
Associate, New York
Marc Recht
Partner, Boston

Related Practices & Industries

Emerging Companies
Venture Capital
Life Sciences
View more

Admissions and credentials

Massachusetts

Rankings and accolades

Chambers USA: Capital Markets – Massachusetts (2014 – 2024)

The Legal 500 US: Healthcare: Life Sciences (2013, 2016, 2020)

Who's Who Legal: Life Sciences (2017, 2018)

Super Lawyers: Rising Star (2007, 2010 – 2013)

Boston Business Journal: Biotech IPO (2015)


Excellent in all categories. Marc Recht is 'very technically skilled in corporate matters and plays a strong quarterback role.'

Legal 500